Tissue Plasminogen Activator Concept

subject area of

• A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator  Journal Articles
• A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease  Journal Articles
• A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage  Journal Articles
• A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism  Journal Articles
• Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction  Journal Articles
• Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets  Journal Articles
• Acute Ischemic Stroke Therapy Overview  Journal Articles
• Acute stroke management.  Journal Articles
• Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.  Journal Articles
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction  Journal Articles
• Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines  Journal Articles
• Aspirin improves the outcome of intra-arterial thrombolysis with tissue plasminogen activator  Journal Articles
• Benefit-risk ratios in the assessment of the clinical evidence of a new therapy  Journal Articles
• Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study  Journal Articles
• Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis  Journal Articles
• Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E  Journal Articles
• Combining Early Ischemic Change and Collateral Extent for Functional Outcomes After Endovascular Therapy: An Analysis From AcT Trial  Journal Articles
• Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction)  Journal Articles
• Consent-Related Outcomes in the Alteplase Compared to Tenecteplase Trial.  Journal Articles
• Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial  Journal Articles
• Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion  Journal Articles
• Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?  Journal Articles
• Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)?  Journal Articles
• Dual surface modification of polydimethylsiloxane (PDMS) with antithrombin-heparin complex (ATH) and tissue plasminogen activator (t-PA) for enhanced antithrombotic activity.  Journal Articles
• Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction.  Journal Articles
• Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial  Journal Articles
• Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle  Journal Articles
• Effectiveness and safety of abciximab after failed thrombolytic therapy  Journal Articles
• Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema  Journal Articles
• Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.  Journal Articles
• Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.  Journal Articles
• Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD  Journal Articles
• Embolization of the deep cervical collaterals—a unique endovascular approach to prevent repeated posterior fossa strokes refractory to medical therapy  Journal Articles
• Emergence of the Primary Pediatric Stroke Center  Journal Articles
• Endovascular Thrombectomy for Acute Ischemic Stroke  Journal Articles
• Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline  Journal Articles
• Endovascular thrombectomy with or without intravenous alteplase for acute ischemic stroke due to large vessel occlusion: a systematic review and meta-analysis of randomized trials  Journal Articles
• Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis  Journal Articles
• FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION  Journal Articles
• Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial.  Journal Articles
• Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists  Journal Articles
• Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.  Journal Articles
• Fibrinolytic System in Adolescents: Response to Venous Occlusion Stress Tests  Journal Articles
• Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study  Journal Articles
• Fibrinolytic properties of lysine‐derivatized polyethylene in contact with flowing whole blood (Chandler loop model)  Journal Articles
• Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease  Journal Articles
• Final Results of the RHAPSODY Trial: A Multi‐Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A‐APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke  Journal Articles
• Good is not Good Enough: The Benchmark Stroke Door-to-Needle Time Should be 30 Minutes  Journal Articles
• Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group.  Journal Articles
• Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.  Journal Articles
• Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells  Journal Articles
• Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.  Journal Articles
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction  Journal Articles
• Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator  Journal Articles
• Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus  Journal Articles
• Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients  Journal Articles
• In acute ischemic stroke, early intraarterial treatment plus usual care improved functional independence  Journal Articles
• In intermediate-risk acute PE, tenecteplase plus heparin reduced hemodynamic decompensation but increased stroke.  Journal Articles
• In ischemic stroke, early intraarterial treatment plus alteplase improved reperfusion and functional outcome  Journal Articles
• In-Hospital Delays for Acute Stroke Treatment Delivery During the COVID-19 Pandemic  Journal Articles
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients  Journal Articles
• Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism  Journal Articles
• Interactions of fibrinolytic system proteins with lysine‐containing surfaces  Journal Articles
• Interactions of plasminogen and fibrinogen with model silica glass surfaces: Adsorption from plasma and enzymatic activity studies  Journal Articles
• Intra-arterial Prourokinase for Acute Ischemic Stroke  Journal Articles
• Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial  Journal Articles
• Intravenous alteplase versus tenecteplase in patients with acute posterior circulation strokes: A secondary analysis from the AcT randomized controlled trial.  Journal Articles
• Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial  Journal Articles
• Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial  Journal Articles
• Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity  Journal Articles
• Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.  Journal Articles
• Limited Fibrin Specificity of Tissue-type Plasminogen Activator and Its Potential Link to Bleeding  Journal Articles
• Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study.  Journal Articles
• Lysis of surface-localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator  Journal Articles
• Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke.  Journal Articles
• Mechanism of Action of Plasminogen Activators  Journal Articles
• Now You See It, Now You Don’t?  Journal Articles
• Outcome Evaluation of Acute Ischemic Stroke Patients Treated with Endovascular Thrombectomy: A Single-Institution Experience in the Era of Randomized Controlled Trials  Journal Articles
• Overutilization and underutilization of thrombolysis in routine clinical practice∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  Journal Articles
• Patterns of Stroke Transfers and Identification of Predictors for Thrombectomy  Journal Articles
• Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis  Journal Articles
• Plasma Urokinase Antigen and Plasminogen Activator Inhibitor-1 Antigen Levels Predict Angiographic Coronary Restenosis  Journal Articles
• Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor.  Journal Articles
• Practical Model-Based Dose Finding in Early-Phase Clinical Trials  Journal Articles
• Pre Admission Antithrombotics are Associated with Improved Outcomes following Ischaemic Stroke: A Cohort from the Registry of the Canadian Stroke Network  Journal Articles
• Predicting tissue plasminogen activator use and success in in-center hemodialysis patients  Journal Articles
• Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial  Journal Articles
• Randomized Comparison of Direct Thrombin Inhibition Versus Heparin in Conjunction With Fibrinolytic Therapy for Acute Myocardial Infarction: Results From the GUSTO-IIb Trial  Journal Articles
• Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.  Journal Articles
• Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis  Journal Articles
• Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial  Journal Articles
• Reducing Door-to-Needle Time for Tissue Plasminogen Activator Administration in a Community Hospital: An Operations Study  Journal Articles
• Regulation of plasminogen activator inhibitor‐1 secretion by urokinase and tissue plasminogen activator in rat epithelioid‐type smooth muscle cells  Journal Articles
• Response to “Effect of Tissue Plasminogen Activator Dose and Interval on Stroke Severity”  Journal Articles
• Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity The STILE Trial  Journal Articles
• Safety and Efficacy of Intravenous Thrombolysis by Infarct Type in Patients with No Visible Occlusion: A Secondary Analysis of the AcT Trial.  Journal Articles
• Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke  Journal Articles
• Safety and efficacy of tenecteplase versus alteplase in stroke patients with carotid tandem lesions: Results from the AcT trial  Journal Articles
• Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial.  Journal Articles
• Seizures during stroke thrombolysis heralding dramatic neurologic recovery  Journal Articles
• Selection and in vitro and in vivo characterization of a Kunitz protease inhibitor domain of protease nexin 2 variant that inhibits factor XIa without inhibiting plasmin  Journal Articles
• Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase  Journal Articles
• Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.  Journal Articles
• Stability and sterility of recombinant tissue plasminogen activator at −30°C  Journal Articles
• Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis  Journal Articles
• Successful Use of Thrombolysis in an Extremely Low Birth Weight, Premature Infant With Aortic Thrombosis  Journal Articles
• Successful delayed thrombolysis with tissue plasminogen activator for recurrent arterial thrombosis secondary to protein S deficiency  Journal Articles
• Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure  Journal Articles
• Surgical management of submacular hemorrhage: experience at an academic Canadian centre  Journal Articles
• Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies  Journal Articles
• Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.  Journal Articles
• Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial  Journal Articles
• The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model  Journal Articles
• The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction  Journal Articles
• The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial  Journal Articles
• The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial  Journal Articles
• The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease  Journal Articles
• The role of platelets and platelet inhibition in acute myocardial infarction  Journal Articles
• The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits  Journal Articles
• The treatment effect across ASPECTS in acute ischemic stroke: Analysis from the AcT Trial  Journal Articles
• The use of alteplase to restore patency of central venous lines in pediatric patients: A cohort study  Journal Articles
• Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors  Journal Articles
• Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator  Journal Articles
• Thrombolysis Despite Recent Stroke  Journal Articles
• Thrombolysis by chemically modified coagulation factor Xa  Journal Articles
• Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.  Journal Articles
• Thrombolysis in Acute Childhood Stroke: Design and Challenges of the Thrombolysis in Pediatric Stroke Clinical Trial  Journal Articles
• Thrombolysis in Pediatric Stroke Study  Journal Articles
• Thrombolysis with alteplase 3–4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances  Journal Articles
• Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated?  Journal Articles
• Thrombolytic therapy for the treatment of acute pulmonary embolism.  Journal Articles
• Tissue Plasminogen Activator (rt-PA) vs Heparin in Deep Vein Thrombosis  Journal Articles
• Tissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes  Journal Articles
• Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers  Journal Articles
• Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.  Journal Articles
• Tissue plasminogen activator-containing polyurethane surfaces for fibrinolytic activity  Journal Articles
• Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction  Journal Articles
• Treatment of acute ischemic stroke: from fibrinolysis to neurointervention  Journal Articles
• Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin  Journal Articles
• Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study  Journal Articles
• Use of thrombolytic agents to treat neonatal thrombosis in clinical practice  Journal Articles
• Utility of Intravenous Alteplase Prior to Endovascular Stroke Treatment  Journal Articles
• Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation  Journal Articles
• [Canadian Consensus Conference on Coronary Thrombolysis--current aspects].  Journal Articles